National Institute of Advanced Industrial Science and Technology

Tokyo Medical University

The University of Toyama

Public University Corporation Nagoya City University

National Center for Global Health and Medicine

Science & Technology Corporation

Glycobiomarker Leading Innovation Co., Ltd.

National Institute of Advanced Industrial

Akira Togayachi

Hisashi Narimatsu

Yuzuru Ikehara

Atsushi Kuno

Hiroyuki Kaji

Maki Sogabe

Niro Inaba

Takashi Ohkura

Toru Hiruma

Masayuki Noguchi

Masaharu Nomura

Masashi Mizokami

Hideki Matsuzaki

Toru Nakanishi

Yasuko Ishizuka

Yoshitoshi Hirao

Jun Iwaki

Minako Abe

Tomomi Kubota

Hiromichi Sawaki

Hayao Nakanishi

Takashi Sato

Yasunori Chiba

Jun Hirabayashi

Yasuhito Tanaka

Makoto Ochou

Toshihide Shikanai

Takashi Angata

Takashi Kudo

Kiyohiko Angata

Hiroki Shimizu

Takanori Wagatsuma

Masaaki Korenaga

Kazuto Tajiri

Tatsuhiko Ozawa

An examination system that recognizes a glycosylated antigen in Dane particles of hepatitis B virus (HBV) and a neutralizing antibody that recognizes the glycosylated antigen and that exhibits an infection-inhibiting activity. It was elucidated that Dane particles are associated with specific glycan structures, and this enabled the construction of a new detection system for infectious, i.e., nucleic acid-containing, hepatitis B virus particles and the provision of a neutralizing antibody that recognizes a glycosylated antigen and that exhibits an infection-inhibiting activity.

Method for efficiently inducing antibody, antibody and detection system for hepatitis virus

An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.

Lung cancer differential marker

It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-&#x3b2;1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase &#x3b2;1,6-N-acetylglucosaminyltransferase 5B as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.

Antibody for detecting epithelial ovarian cancer marker and method for diagnosing epithelial ovarian cancer

The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-&#x3b2;1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase &#x3b2;1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.

The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.

Glycan markers as measure of disease state of hepatic diseases

The N-acetyl-D-galactosamine transferase protein of the present invention is characterized by transferring N-acetyl-D-galactosamine to N-acetyl-D-glucosamine with &#x3b2;1,3 linkage, and it preferably has the amino acid sequence shown in SEQ ID NO: 2 or 4. The canceration assay according to the present invention uses a nucleic acid for measurement which hybridizes under stringent conditions to the nucleotide sequence shown in SEQ ID NO: 1 or 3 or a nucleotide sequence complementary to at least one of them.

&#x3b2;1,3-N-acetyl-D-galactosamine transferase protein, nucleic acid encoding the same and method of examining canceration using the same

A tumor marker nucleic acid of the present invention is concerned with a nucleic acid hybridizing under stringent conditions to a nucleotide sequence described in SEQ ID NO: 1 or a complementary nucleotide sequence thereof. A method of testing canceration of the present invention is a method comprising diagnosing a biological sample as being cancerous when the transcription level of the nucleic acid in the biological sample significantly exceeds that in a normal biological sample as a control. The present invention also relates to a &#x3b2;1,3-N-acetyl-D-glucosaminyltransferase protein having an activity of transferring N-acetyl-D-glucosamine from a donor substrate to an acceptor substrate through &#x3b2;1,3-linkage.

Glycosyltransferase, nucleic acid encoding the glycosyltransferase and method of testing canceration using the nucleic acid

An enzyme having an activity of transferring N-acetylglucosamine to the non-reducing end of a Gal&#x3b2;1-4Glc or Gal&#x3b2;1-4GlcNAc-group via a &#x3b2;-1,3 bond; a nucleic acid encoding the same; and a method of diagnosing cancer and/or tumor, in particular, digestive cancer and/or tumor using the expression dose of a gene of the above enzyme as an indication. A gene of a novel enzyme having an activity of transferring N-acetylglucosamine to the non-reducing end of a Gal &#x3b2;1-4Glc or Gal &#x3b2;1-4GlcNAc-group via a &#x3b2;-1,3 bond is cloned from human stomach cells and its base sequence is determined. Then this enzyme is expressed. Since this enzyme is scarcely or never produced in cancer and/or tumor, in particular, digestive cancer and/or tumor cells, cancer and/or tumor can be diagnosed with the use of the expression of the enzyme gene as an indication.

N-acetylglucosamine transferase, nucleic acid encoding the same and use thereof in diagnosing cancer and/or tumor

Growing community of inventors

Tsukuba, Japan

Akira Togayachi